| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| MANNKIND CORP | Chief Financial Officer | Common Stock, $0.01 Par Value | 343,854 | $1,323,837 | $3.85 | 15 Jul 2025 | Direct |
| MANNKIND CORP | Chief Financial Officer | Performance Restricted Stock Unit | 145,000 | 13 May 2025 | Direct | ||
| Adamas Pharmaceuticals Inc | Chief Financial Officer | Common Stock | 0 | $5.16 | 24 Nov 2021 | Direct | |
| Adamas Pharmaceuticals Inc | Chief Financial Officer | Stock Option (Right to Buy) | 0 | 24 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| MNKD | MANNKIND CORP | 15 Jul 2025 | 1 | -$44,429 | 4 | Chief Financial Officer | 17 Jul 2025, 20:45 |
| MNKD | MANNKIND CORP | 13 May 2025 | 2 | $0 | 4 | Chief Financial Officer | 15 May 2025, 20:34 |
| MNKD | MANNKIND CORP | 15 May 2024 | 1 | $0 | 4/A | Chief Financial Officer | 28 Mar 2025, 20:20 |
| MNKD | MANNKIND CORP | 22 Apr 2024 | 0 | $0 | 3 | Chief Financial Officer | 22 Apr 2024, 19:00 |
| /report/000132814321000092-prentiss-christopher-b-2021-11-24 | Adamas Pharmaceuticals Inc | 24 Nov 2021 | 4 | $0 | 4 | Chief Financial Officer | 24 Nov 2021, 15:10 |